Pocared Diagnostics Ltd., a Rehovot, Israeli-based diagnostics and pre-analytical technology manufacturer, closed $15M in milestone-based funding.
The company intends to use the funds to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000TM and SP platforms.
Led by Jonathan Gurfinkel, President and CEO, Pocared Diagnostics develops technology platforms that aim to improve the ability of practitioners and hospitals to implement evidence-based medicine, while reducing lab operating costs and improving profitability. The POCARED P-1000TM analysis platform offers direct- specimen, fully automated, reagent-free microorganism detection, identification and enumeration for bacteria and yeast by utilizing intrinsic fluorescence optical data.
The company also has offices in the USA.